AKEBIA THERAPEUTICS, INC. (AKBA) Scorecard
- 2026-Q2: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2026-Q1: Total return Lose; Revenue growth Win; EPS growth Lose.
- 2025-Q4: Total return Lose; Revenue growth Win; EPS growth Lose.
- 2025-Q3: Total return Lose; Revenue growth Win; EPS growth Lose.
34/120
All 120 Win/Lose results shown below
Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
Trailing 1 year (4 quarters): 3 wins, 9 lossesLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q20/3 |
LoseAKBA / S&P -17.99% / 15.20% |
LoseAKBA / S&P 7.52% / 15.00% |
LoseAKBA / S&P -38.89% / 50.40% |
| 2026-Q11/3 |
LoseAKBA / S&P -13.66% / -4.33% |
WinAKBA / S&P 25.69% / 11.30% |
LoseAKBA / S&P -63.64% / 27.70% |
| 2025-Q41/3 |
LoseAKBA / S&P -41.03% / 2.65% |
WinAKBA / S&P 47.46% / 9.00% |
LoseAKBA / S&P -94.12% / 13.40% |
| 2025-Q31/3 |
LoseAKBA / S&P -25.00% / 8.12% |
WinAKBA / S&P 32.49% / 4.61% |
LoseAKBA / S&P -65.22% / 13.45% |
| 2025-Q22/3 |
WinAKBA / S&P 89.58% / 10.94% |
WinAKBA / S&P 16.75% / 4.83% |
LoseAKBA / S&P -14.29% / 10.63% |
| 2025-Q11/3 |
WinAKBA / S&P 1.05% / -4.27% |
LoseAKBA / S&P -1.24% / 4.98% |
LoseAKBA / S&P -4.35% / 10.57% |
| 2024-Q42/3 |
WinAKBA / S&P 43.94% / 2.41% |
LoseAKBA / S&P -17.70% / 5.25% |
WinAKBA / S&P 17.24% / 6.15% |
| 2024-Q31/3 |
WinAKBA / S&P 29.41% / 5.89% |
LoseAKBA / S&P -12.53% / 5.89% |
LoseAKBA / S&P -30.30% / 6.11% |
| 2024-Q20/3 |
LoseAKBA / S&P -44.26% / 4.28% |
LoseAKBA / S&P -13.13% / 5.38% |
LoseAKBA / S&P -61.11% / 5.12% |
| 2024-Q11/3 |
WinAKBA / S&P 47.58% / 10.56% |
LoseAKBA / S&P -30.88% / 5.71% |
LoseAKBA / S&P -30.30% / 5.59% |
| 2023-Q40/3 |
LoseAKBA / S&P 8.77% / 11.69% |
LoseAKBA / S&P -33.48% / 6.81% |
LoseAKBA / S&P -45.28% / 7.78% |
| 2023-Q31/3 |
WinAKBA / S&P 24.59% / -3.27% |
LoseAKBA / S&P -34.47% / 7.52% |
LoseAKBA / S&P -62.92% / -5.03% |
| 2023-Q21/3 |
WinAKBA / S&P 63.39% / 8.74% |
LoseAKBA / S&P -32.23% / 9.50% |
LoseAKBA / S&P -42.55% / -8.57% |
| 2023-Q11/3 |
LoseAKBA / S&P -2.95% / 7.50% |
WinAKBA / S&P 21.48% / 10.77% |
LoseAKBA / S&P -79.38% / -15.69% |
| 2022-Q42/3 |
WinAKBA / S&P 82.59% / 7.56% |
WinAKBA / S&P 36.98% / 11.88% |
LoseAKBA / S&P -68.82% / -17.99% |
| 2022-Q31/3 |
LoseAKBA / S&P -10.48% / -4.88% |
WinAKBA / S&P 40.68% / 13.47% |
LoseAKBA / S&P -52.91% / -1.41% |
| 2022-Q21/3 |
LoseAKBA / S&P -50.84% / -16.10% |
WinAKBA / S&P 33.58% / 13.71% |
LoseAKBA / S&P -52.28% / 11.04% |
| 2022-Q10/3 |
LoseAKBA / S&P -68.23% / -4.60% |
LoseAKBA / S&P -13.95% / 15.97% |
LoseAKBA / S&P -41.61% / 42.23% |
| 2021-Q40/3 |
LoseAKBA / S&P -21.53% / 11.03% |
LoseAKBA / S&P -27.68% / 15.00% |
LoseAKBA / S&P AKBA unavailable / 96.40% |
| 2021-Q30/3 |
LoseAKBA / S&P -24.01% / 0.58% |
LoseAKBA / S&P -31.64% / 10.77% |
LoseAKBA / S&P AKBA unavailable / 69.42% |
| 2021-Q21/3 |
WinAKBA / S&P 11.96% / 8.55% |
LoseAKBA / S&P -34.76% / 6.58% |
LoseAKBA / S&P AKBA unavailable / 51.81% |
| 2021-Q11/3 |
WinAKBA / S&P 20.89% / 6.17% |
LoseAKBA / S&P -26.13% / -1.06% |
LoseAKBA / S&P AKBA unavailable / 7.39% |
| 2020-Q40/3 |
LoseAKBA / S&P 11.55% / 12.15% |
LoseAKBA / S&P -11.85% / -3.72% |
LoseAKBA / S&P AKBA unavailable / -33.42% |
| 2020-Q30/3 |
LoseAKBA / S&P -81.52% / 8.93% |
LoseAKBA / S&P -5.27% / -2.04% |
LoseAKBA / S&P AKBA unavailable / -27.10% |
| 2020-Q22/3 |
WinAKBA / S&P 79.16% / 20.54% |
WinAKBA / S&P 18.73% / -0.46% |
LoseAKBA / S&P AKBA unavailable / -27.11% |
| 2020-Q12/3 |
WinAKBA / S&P 19.94% / -19.60% |
WinAKBA / S&P 49.61% / 3.47% |
LoseAKBA / S&P AKBA unavailable / -14.75% |
| 2019-Q42/3 |
WinAKBA / S&P 61.22% / 9.07% |
WinAKBA / S&P 61.26% / 5.36% |
LoseAKBA / S&P AKBA unavailable / 2.99% |
| 2019-Q31/3 |
LoseAKBA / S&P -19.01% / 1.70% |
WinAKBA / S&P 36.42% / 5.02% |
LoseAKBA / S&P AKBA unavailable / 0.21% |
| 2019-Q21/3 |
LoseAKBA / S&P -40.90% / 4.30% |
WinAKBA / S&P 26.45% / 6.64% |
LoseAKBA / S&P AKBA unavailable / 8.65% |
| 2019-Q12/3 |
WinAKBA / S&P 48.10% / 13.65% |
WinAKBA / S&P 13.66% / 8.12% |
LoseAKBA / S&P AKBA unavailable / 14.29% |
| 2018-Q40/3 |
LoseAKBA / S&P -37.37% / -13.52% |
LoseAKBA / S&P AKBA unavailable / 9.05% |
LoseAKBA / S&P AKBA unavailable / 18.23% |
| 2018-Q30/3 |
LoseAKBA / S&P -11.52% / 7.71% |
LoseAKBA / S&P AKBA unavailable / 10.21% |
LoseAKBA / S&P AKBA unavailable / 19.06% |
| 2018-Q21/3 |
WinAKBA / S&P 4.72% / 3.43% |
LoseAKBA / S&P AKBA unavailable / 9.03% |
LoseAKBA / S&P AKBA unavailable / 14.46% |
| 2018-Q10/3 |
LoseAKBA / S&P -35.91% / -0.76% |
LoseAKBA / S&P AKBA unavailable / 7.68% |
LoseAKBA / S&P AKBA unavailable / 12.46% |
| 2017-Q40/3 |
LoseAKBA / S&P -24.40% / 6.64% |
LoseAKBA / S&P AKBA unavailable / 7.03% |
LoseAKBA / S&P AKBA unavailable / 13.82% |
| 2017-Q31/3 |
WinAKBA / S&P 36.88% / 4.48% |
LoseAKBA / S&P AKBA unavailable / 5.68% |
LoseAKBA / S&P AKBA unavailable / 17.57% |
| 2017-Q21/3 |
WinAKBA / S&P 56.20% / 3.09% |
LoseAKBA / S&P AKBA unavailable / 4.83% |
LoseAKBA / S&P AKBA unavailable / 17.74% |
| 2017-Q10/3 |
LoseAKBA / S&P -11.62% / 6.07% |
LoseAKBA / S&P AKBA unavailable / 3.67% |
LoseAKBA / S&P AKBA unavailable / 13.32% |
| 2016-Q41/3 |
WinAKBA / S&P 15.03% / 3.82% |
LoseAKBA / S&P AKBA unavailable / 2.09% |
LoseAKBA / S&P AKBA unavailable / 7.05% |
| 2016-Q31/3 |
WinAKBA / S&P 20.99% / 3.85% |
LoseAKBA / S&P AKBA unavailable / 0.20% |
LoseAKBA / S&P AKBA unavailable / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | AKBA total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -70.06% | 20.78% |
| Annualized return | -70.06% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | AKBA total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -69.18% | 83.14% |
| Annualized return | -20.97% | 12.86% |
10Y · 2016-09-01 to 2026-08-27
| Metric | AKBA total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -88.41% | 319.30% |
| Annualized return | -19.39% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |